These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 10471207)

  • 1. Cerebrospinal fluid levels of thiamine in patients with Parkinson's disease.
    Jiménez-Jiménez FJ; Molina JA; Hernánz A; Fernández-Vivancos E; de Bustos F; Barcenilla B; Gómez-Escalonilla C; Zurdo M; Berbel A; Villanueva C
    Neurosci Lett; 1999 Aug; 271(1):33-6. PubMed ID: 10471207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrospinal fluid levels of thiamine in patients with Alzheimer's disease.
    Molina JA; Jiménez-Jiménez FJ; Hernánz A; Fernández-Vivancos E; Medina S; de Bustos F; Gómez-Escalonilla C; Sayed Y
    J Neural Transm (Vienna); 2002 Jul; 109(7-8):1035-44. PubMed ID: 12111441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Normal cerebrospinal fluid levels of insulin in patients with Parkinson's disease.
    Jiménez-Jiménez FJ; Molina JA; Vargas C; Gómez P; De Bustos F; Zurdo M; Gómez-Escalonilla C; Barcenilla B; Berbel A; Camacho A; Arenas J
    J Neural Transm (Vienna); 2000; 107(4):445-9. PubMed ID: 11215755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal fluid levels of transition metals in patients with Parkinson's disease.
    Jiménez-Jiménez FJ; Molina JA; Aguilar MV; Meseguer I; Mateos-Vega CJ; González-Muñoz MJ; de Bustos F; Martínez-Salio A; Ortí-Pareja M; Zurdo M; Martínez-Para MC
    J Neural Transm (Vienna); 1998; 105(4-5):497-505. PubMed ID: 9720977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebrospinal fluid cyclic guanosine 3'5' monophosphate levels in Parkinson's disease.
    Navarro JA; Jiménez-Jiménez FJ; Molina JA; Benito-León J; Cisneros E; Gasalla T; Ortí-Pareja M; Tallón-Barranco A; de Bustos F; Arenas J
    J Neurol Sci; 1998 Feb; 155(1):92-4. PubMed ID: 9562329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrospinal fluid selenium and chromium levels in patients with Parkinson's disease.
    Aguilar MV; Jiménez-Jiménez FJ; Molina JA; Meseguer I; Mateos-Vega CJ; González-Muñoz MJ; de Bustos F; Gómez-Escalonilla C; Ort-Pareja M; Zurdo M; Martínez-Para MC
    J Neural Transm (Vienna); 1998; 105(10-12):1245-51. PubMed ID: 9928893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebrospinal fluid levels of alpha-tocopherol (vitamin E) in Parkinson's disease.
    Molina JA; de Bustos F; Jiménez-Jiménez FJ; Benito-León J; Ortí-Pareja M; Gasalla T; Tallón-Barranco A; Navarro JA; Arenas J; Enríquez-de-Salamanca R
    J Neural Transm (Vienna); 1997; 104(11-12):1287-93. PubMed ID: 9503274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal fluid carnitine levels in patients with Parkinson's disease.
    Jiménez-Jiménez FJ; Rubio JC; Molina JA; Martín MA; Campos Y; Benito-León J; Ortí-Pareja M; Gasalla T; Arenas J
    J Neurol Sci; 1997 Feb; 145(2):183-5. PubMed ID: 9094047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal fluid nitrate levels in patients with Parkinson's disease.
    Molina JA; Jiménez-Jiménez FJ; Navarro JA; Vargas C; Gómez P; Benito-León J; Ortí-Pareja M; Cisneros E; Arenas J
    Acta Neurol Scand; 1996; 93(2-3):123-6. PubMed ID: 8741130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated 5-S-cysteinyldopamine/homovanillic acid ratio and reduced homovanillic acid in cerebrospinal fluid: possible markers for and potential insights into the pathoetiology of Parkinson's disease.
    Cheng FC; Kuo JS; Chia LG; Dryhurst G
    J Neural Transm (Vienna); 1996; 103(4):433-46. PubMed ID: 9617787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal fluid levels of catecholamines and its metabolites in Parkinson's disease: effect of l-DOPA treatment and changes in levodopa-induced dyskinesia.
    Andersen AD; Blaabjerg M; Binzer M; Kamal A; Thagesen H; Kjaer TW; Stenager E; Gramsbergen JBP
    J Neurochem; 2017 May; 141(4):614-625. PubMed ID: 28244186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Homovanillic acid in CSF of mild stage Parkinson's disease patients correlates with motor impairment.
    Stefani A; Pierantozzi M; Olivola E; Galati S; Cerroni R; D'Angelo V; Hainsworth AH; Saviozzi V; Fedele E; Liguori C
    Neurochem Int; 2017 May; 105():58-63. PubMed ID: 28108196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of rasagiline and selegiline in Parkinson's disease: a head-to-head 3-year retrospective case-control study.
    Cereda E; Cilia R; Canesi M; Tesei S; Mariani CB; Zecchinelli AL; Pezzoli G
    J Neurol; 2017 Jun; 264(6):1254-1263. PubMed ID: 28550482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreased cerebrospinal fluid levels of neutral and basic amino acids in patients with Parkinson's disease.
    Molina JA; Jiménez-Jiménez FJ; Gomez P; Vargas C; Navarro JA; Ortí-Pareja M; Gasalla T; Benito-León J; Bermejo F; Arenas J
    J Neurol Sci; 1997 Sep; 150(2):123-7. PubMed ID: 9268238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Attempts to obtain neuroprotection in Parkinson's disease.
    Olanow CW
    Neurology; 1997 Jul; 49(1 Suppl 1):S26-33. PubMed ID: 9222272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group.
    Rinne UK; Bracco F; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL; Marsden CD
    Drugs; 1998; 55 Suppl 1():23-30. PubMed ID: 9483167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of cerebrospinal fluid from patients with Parkinson disease on dopaminergic cells.
    Le WD; Rowe DB; Jankovic J; Xie W; Appel SH
    Arch Neurol; 1999 Feb; 56(2):194-200. PubMed ID: 10025424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subthalamic Nucleus Deep Brain Stimulation Modulate Catecholamine Levels with Significant Relations to Clinical Outcome after Surgery in Patients with Parkinson's Disease.
    Yamamoto T; Uchiyama T; Higuchi Y; Asahina M; Hirano S; Yamanaka Y; Kuwabara S
    PLoS One; 2015; 10(9):e0138462. PubMed ID: 26394059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of dopaminergic treatment on bladder function in Parkinson's disease.
    Winge K; Werdelin LM; Nielsen KK; Stimpel H
    Neurourol Urodyn; 2004; 23(7):689-96. PubMed ID: 15382192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tau protein concentrations in cerebrospinal fluid of non-demented Parkinson's disease patients.
    Molina JA; Benito-León J; Jiménez-Jiménez FJ; Ortí-Pareja M; Berbel A; Tallón-Barranco A; de Bustos F; Hernánz A
    Neurosci Lett; 1997 Dec; 238(3):139-41. PubMed ID: 9464639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.